Paricalcitol Intravenous for Adults

Who can administer

May be administered by registered competent doctor or nurse/midwife

Important information

  • Purchased by pharmacy only on consultant's request

Available preparations

Zemplar 5microgram in 1ml (other strengths available but NOT routinely stocked)


Already in solution

Draw up using a 5 micron filter needle

Infusion fluids

Not required

Methods of intravenous administration

  • Give as a slow intravenous bolus via haemodialysis access

Dose in adults

Depends on baseline parathyroid hormone (PTH) levels and units used to express PTH levels (see table below):


Initial dose

PTH measured in pmol/l (see below for dose) PTH measured in pg/ml (see below for dose)
Initial dose (micrograms)= baseline intact PTH (pmol/l) / 8 Initial dose (micrograms) = baseline intact PTH (pg/ml) / 80
  • Should be administered every second day (maximum).
  • The maximum dose safely administered in clinical studies was 40 micrograms.

Use in NON-haemodialysis patients is outside the product license. Therefore dosing recommendations may not be appropriate. In such circumstances laboratory monitoring is critical.



Titration dose: suggested guidelines based on intact PTH (iPTH) below

Dosage adjustments should be made every 2 to 4 weeks 
iPTH level relative to baseline Paricalcitol dose adjustment 
Same or increased   Increase by 2 to 4  micrograms
Decreased by LESS than 30%
Decreased by 30 to 60%  Maintain
Decreased by GREATER than 60%  Decrease by 2 to 4 micrograms
iPTH LESS than 15.9 pmol/l (150pg/ml) 

In patients with clinically significant hypercalcaemia, consider cessation or a reduction in dose of the paricalcitol (see SPC for further details).


Suggested monitoring during maintenance phase (below)

Parameter Monitoring frequency
Calcium and phosphate At least monthly 
Serum intact PTH (iPTH) Three monthly

During the titration phase monitoring may be required more frequently

Further information

  • Zemplar injection also contains ethanol (20% v/v) and propylene glycol (consult with prescriber in high risk groups- eg alcoholics, liver disease, epilepsy)
  • Avoid giving heparin via the same port as propylene glycol may neutralise its effect


No particular storage requirements


SPC July 2018

Therapeutic classification

Synthetic, biologically active vitamin D analog of calcitriol